Health-related quality of life for everolimus versus placebo in patients with advanced, non-functional, well-differentiated gastrointestinal or lung neuroendocrine tumours (RADIANT-4): a multicentre, randomised, double-blind, placebo-controlled, phase 3 trial
Pavel, Marianne E, Singh, Simron, Strosberg, Jonathan R, Bubuteishvili-Pacaud, Lida, Degtyarev, Evgeny, Neary, Maureen P, Carnaghi, Carlo, Tomasek, Jiri, Wolin, Edward, Raderer, Markus, Lahner, HaraldLangue:
english
Journal:
The Lancet Oncology
DOI:
10.1016/S1470-2045(17)30471-0
Date:
August, 2017
Fichier:
PDF, 408 KB
english, 2017